Small Molecule Innovator API CDMO Market To Reach $43.75 Billion By 2033

Small Molecule Innovator API CDMO Market Growth & Trends

The global small molecule innovator API CDMO market size is estimated to reach USD 43.75 billion by 2033, expanding at a CAGR of 6.55% from 2026 to 2033, according to a new report by Grand View Research, Inc. A growing outsourcing trend among pharmaceutical companies, increasing demand for small molecule drugs, and a surge in the number of clinical trials are anticipated to influence the market positively. The growing utilization of CDMOs in the pharmaceutical sector stems from various reasons, with cost-effectiveness as the prominent factor. Outsourcing emerges as an efficient strategy for pharmaceutical firms to reduce expenses by sidestepping the necessity for costly infrastructure and equipment investments. CDMOs offer the requisite expertise and infrastructure to deliver drug development and manufacturing services in a financially prudent manner.

Furthermore, enhanced efficiency serves as another pivotal driver for pharmaceutical outsourcing. With mounting pressure on pharmaceutical companies to expedite the introduction of new drugs to the market, outsourcing emerges as a solution to accelerate the drug development process. Leveraging their expertise, experience, and cutting-edge equipment, CDMOs facilitate the swift & efficient production of high-quality drugs, enabling pharmaceutical firms to adhere to their development schedules. In addition, several pharmaceutical companies prefer CDMOs to access advanced infrastructure and expertise due to the increasing influx of novel therapies & orphan drugs and higher returns on approved products. Moreover, continuous technological advancements among CDMOs offer innovative small molecule APIs to meet the growing demands for innovation, efficiency, and regulatory compliance in the healthcare industry.

The adoption of advanced technologies by companies enhances drug development, manufacturing processes, and productivity. The increasing demand for new small molecule innovator API in the pharmaceutical industry is encouraging commercial CDMOs to expand their capabilities, which is expected to boost market growth. For instance, in August 2023, Astex announced a research collaboration & license agreement with MSD to classify small molecule candidates with tumor suppressor proteins for cancer treatment. Under the agreement, the company will use its fragment-based drug discovery platform to develop compounds and provide MSD with main compounds for preclinical development & optimization.

 Request a free sample copy or view report summary: Small Molecule Innovator API CDMO Market Report

Small Molecule Innovator API CDMO Market Report Highlights

• HighlightsThe small molecule API segment is anticipated to register the fastest CAGR over the forecast period. This growth can primarily be attributed to the high approval rate of NME small molecules by regulatory agencies

• The clinical stage segment held the largest revenue share in 2025. CDMOs offer specialized expertise, time-saving, and cost-efficiency during clinical procedures. This is expected to augment the segmental growth over the forecast period

• Based on customer type, the market is segregated into pharmaceutical and biotechnology. The pharmaceutical segment held the largest revenue share in 2025. The growing focus on pharmaceutical companies to focus on core competencies, such as sales and adoption of expansion strategies by CDMOs for manufacturing small molecule drugs, are promoting the segment’s market growth

• The clinical segment led small molecule innovator API CDMO market and accounted for 54.44% of global revenue in 2025. The clinical segment is further sub-segmented to Phase I, Phase II, and Phase III.

Small Molecule Innovator API CDMO Market Segmentation

Grand View Research has segmented the global small molecule innovator API CDMO market based on stage type, customer type, therapeutic area and region:

Small Molecule Innovator API CDMO Stage Type Outlook (Revenue, USD Million, 2021 - 2033)

• Preclinical

• Clinical

  • Phase I

  • Phase II

  • Phase III

• Commercial

Small Molecule Innovator API CDMO Customer Type Outlook (Revenue, USD Million, 2021 - 2033)

• Pharmaceutical

  • Small

  • Medium

  • Large

• Biotechnology

  • Small

  • Medium

  • Large

Small Molecule Innovator API CDMO Therapeutic Area Outlook (Revenue, USD Million, 2021 - 2033)

• Cardiovascular Diseases

• Oncology

• Respiratory Disorders

• Neurology

• Metabolic Disorders

• Infectious Diseases

• Others

Small Molecule Innovator API CDMO Regional Outlook (Revenue, USD Million, 2021 - 2033)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • China

  • Japan

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

  • Oman

  • Qatar

List of Key Players in the Small Molecule Innovator API CDMO Market

• Lonza Group Ltd.

• Novo Holdings (Catalent, Inc.)

• Thermo Fisher Scientific, Inc.

• Siegfried Holding AG

• Recipharm AB

• CordenPharma International

• Samsung Biologics

• Labcorp

• Ajinomoto Bio-Pharma Services

• Piramal Pharma Solutions

• Jubilant Life Sciences (Jubilant Biosys Limited)

• WuXi AppTec Co., Ltd.